Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7279)	12/11/1999 1:59:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

Re We still need to know why bex gives those late responses. Any updates on the rationale that Peter suggested, based on C2B8 residency? Yes, we need to find this out, or, more likely, come up with some kind of non-laughable hypothesis. C2B8 (aka Rituxan) residency? I am afraid you lost me here. Recapping, in the Flu protocols known to me we have: (1) Flu3+Bex give 3 cycles of Flu, wait several weeks (half-life of Flu? I'd guess less than 1-2 weeks), give Bexxar treatment. I see little chance for the 2 agents (MAb and flu) to coexist. (2) Flu6+Rit give 6 cycles of Flu overlapped with cycles of Rit. Two agents do exist. Once you remember (thanks V1) that it is 3 versus 6 cycles the "mystery" of why the Rit regime may be more toxic evaporates. We don't even need to think too much about the co-existence issue. PB